A thyroid imaging reporting and data system was created for risk stratification of thyroid nodules according to qualitative nonenhanced and contrast-enhanced US features. Background The role of contrast-enhanced US (CEUS) in reducing unnecessary biopsies of thyroid nodules has received little attention. Purpose To construct and externally validate a thyroid imaging ...
Purpose: This study aimed to analyze the ultrasonographic characteristics of differentiated thyroid cancer (DTC) with multigenic co-mutations and to establish a predictive model using contrast-enhanced ultrasonography (CEUS).Methods: This retrospective study included consecutive patients with pathologically confirmed DTC who underwent preoperative CEUS and next-generation sequencing at the authors’ institution between September 2021 and December 2023. Clinical and CEUS features were compared between patients with and without multigenic co-mutations. Bayesian logistic regression (non-informative normal priors) was applied for predictor selection and model development, with Markov-chain Monte Carlo (MCMC) convergence checks and posterior predictive validation. Internal validation was performed using bootstrap resampling (n=1,000 iterations) to evaluate model stability.Results: A total of 116 patients (mean age, 39.84±11.02 years; 33 men) were included, of whom 12 had multigenic co-mutations and 104 did not. Patients with multigenic co-mutations demonstrated a higher incidence of aggressive histological subtypes (25.0% vs. 1.9%, P=0.008) and lymph node metastasis (83.3% vs. 51.9%, P=0.038). Tumor size, enhancement homogeneity, and contrast agent arrival time were identified as significant predictors, with robust posterior distributions (all inclusion probabilities >0.9) and satisfactory MCMC convergence (potential scale reduction factor <1.01). The model achieved an area under the curve (AUC) of 0.873, with posterior predictive checks confirming favorable predicted-observed agreement (coverage ≥0.85). Internal validation with 1,000 bootstrap replicates yielded a consistent AUC of 0.880 (95% confidence interval, 0.745 to 0.978).Conclusion: The CEUS-based predictive model demonstrated strong discrimination for detecting multigenic co-mutations in differentiated thyroid cancer; however, external validation is required to confirm its clinical applicability.
In clinical practice, contralateral incidental malignant foci (CIMFs) can be found in some early (cT1N0M0) papillary thyroid carcinomas (PTCs) on postoperative pathological examination. To screen out the patients with high risk of CIMF preoperatively would help in determining the extent of thyroid surgery. From October 2016 to February 2021, 332 patients diagnosed with early (cT1N0M0) PTC who underwent total thyroidectomy were included and randomly allocated into a training dataset (n = 233) and a test dataset (n = 99). Demographic and clinicopathological features were recorded and analyzed using logistic regression analysis. A coefficient-based nomogram was developed and validated. Logistic regression analyses revealed that the predictive model including BRAF V600E mutation, multifocality and margin of the contralateral nodule achieved the best diagnostic performance. The nomogram showed good discrimination, with AUCs of 0.795 (95 % CI, 0.736-0.853) for the training set and 0.726 (95 % CI, 0.609-0.843) for the test set. The calibration curve of the nomogram presented good agreement. The risk stratification system can be used to quantify the probability of CIMF and may assist in helping the patients choose total thyroidectomy or thyroid lobectomy with early (cT1N0M0) PTC.